More

    India Recommends Bharat Biotech’s COVAXIN for Kids Under 12 Years

    Bharat Biotech’s COVID-19 vaccine for children under 12 years of age has got India’s Subject Expert Committee nod. This recommendations given by SEC today makes the first vaccine maker in the country to get such an approval after a review of its trial data for the 2-18 age-group.

    The decision is a big bolster to India’s vaccination program to not only cover adults but also its younger population. Most importantly, vaccinating children against the coronavirus, having already rolled out more than 950 million doses to adults among its population of nearly 1.4 billion.

    Bharat Biotech‘s Covaxin, which uses an inactivated coronavirus with an immunity booster, is among the three shots that are being used in India as part of the vaccination drive for adults.

    More than 110 million doses of Covaxin have been administered and the company is in the process of securing an emergency use listing from the World Health Organization, a decision that is expected later this month.

    Bharat Biotech Covid 19 vaccine is the first in the world for age group from 2-18 years

    COVAXIN
    Covaxin for children under 12 year old gets India SEC recommendation

    “This represents one of the first recommendations worldwide for COVID-19 vaccines for the 2-18 age group. Bharat Biotech sincerely thanks the DCGI, Subject Experts Committee, and CDSCO for their expedited review process. We now await further regulatory approvals from the CDSCO prior to product launch and market availability of Covaxin for children,” Bharat Biotech said in a statement.

    Bharat Biotech has submitted data from clinical trials in the 2-18 years age group for Covaxin (BBV152) to CDSCO. The data has been thoroughly reviewed by the CDSCO and SEC and have provided their positive recommendations, the vaccine maker said.

    “After detailed deliberation, the committee recommended grant of market authorisation of the vaccine for the age group of 2 to 18 years for restricted use in emergency situations subject to the certain conditions,” the SEC recommendations stated.

    The recommendations have been forwarded to the Drugs Controller General of India (DCGI) for final approval.

    Share

    Latest Updates

    Related Articles

    Vizag Tech Summit 2023 announces INR 3000 Cr Projected Investments

    The Vizag Tech Summit 2023 will be held on February 16th and 17th, 2023...

    iNCOVACC Fast Facts: World’s first Intranasal vaccine approved by India

    Bharat Biotech iNCOVACC®️ (BBV154), has received approval from the Central Drugs Standard Control Organisation...

    China’s Foxconn’s factory unrest may lead to serious shortage of iPhone’s

    Foxconn's factory in Zhengzhou, China, is experiencing employee unrest that could lead to a...

    Fear of T20 taking away the best players plagues international cricket

    T20 Cricket is threating national teams globally as players seem to prefer playing T20...